Clinical Advances in Nasopharyngeal Carcinoma - Episode 6

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

, ,

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
EP. 4: Value of PD-L1 Biomarker in NPC
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Now Viewing
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
EP. 10: Clinical Scenario: Locally Recurrent NPC
EP. 11: Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

  • Is there a specific patient population that might benefit from this treatment?
  • Are there any external factors that may impact your treatment selection? Are you monitoring your patients for EBV titer?

Related Content:

Clinical Advances in Nasopharyngeal CarcinomaYale Cancer CenterCity of HopeHead & Neck CancersInsights
Single-Agent Immune Therapy in UC: The Need for More
Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients